{
    "code": "52027432",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027432",
    "time": "2019-11-01 03:03:25",
    "許可證字號": "衛部藥輸字第027432號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "112\/05\/11",
    "發證日期": "107\/05\/11",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202743200",
    "中文品名": "邁若米凍晶注射劑",
    "英文品名": "MYZOMIB",
    "適應症": "1.MYZOMIB可合併其他癌症治療藥品使用於未接受過治療的多發性骨髓瘤(Multiple myeloma)病人及曾接受過至少一種治療方式且已經接受或不適宜接受骨髓移植的進展性多發性骨髓癌病人。2.被套細胞淋巴瘤Muantle Cell Lymphoma (MCL)病人。",
    "劑型": "243凍晶注射劑",
    "包裝": "3.5毫克玻璃小瓶裝 100支以下盒裝",
    "": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "-->\r\n                    \r\n                        \r\n                            標籤、仿單及包裝加註": [
        ""
    ],
    "藥品類別": "05限由醫師使用",
    "主成分略述": "BORTEZOMIB",
    "主製造廠": {
        "申請商名稱": "6201118216  台灣邁蘭有限公司",
        "申請商地址": "台北市內湖區民權東路六段160號8樓之3",
        "主製造廠": "",
        "製造廠名稱": "FIN0921000  MYLAN LABORATORIES LIMITED-OTL"
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013001200",
            "成分名稱": "BORTEZOMIB",
            "含量描述": "(Bortezomib Monohydrate) eq. to",
            "含量": "3.5000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Myzomib PI Final-107-06-13.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027432&Seq=001&Type=9"
        },
        {
            "title": "Myzomib label-107-06-13.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027432&Seq=002&Type=8"
        },
        {
            "title": "Myzomib Carton-107-06-13.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027432&Seq=001&Type=8"
        }
    ]
}